Search

Your search keyword '"Horňák, T."' showing total 7 results
Start Over Author "Horňák, T."
7 results on '"Horňák, T."'

1. Cévní nežádoucí účinky u pacientů s chronickou myeloidní leukemií při terapii inhibitory tyrozinkináz v každodenní klinické praxi – analýza z databáze INFINITY.

Author

Čičátková, P., Žáčková, D., Horňák, T., Klamová, H., Bělohlávková, P., Stejskal, L., Křístková, Z., Baranová, J., Kvetková, A., Semerád, L., Procházková, J., and Mayer, J.

Abstract

Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023

2. Úskalí léčby chronické myeloidní leukemie dasatinibem - plicní arteriální hypertenze jako vzácná komplikace.

Author

Čičátková, P., Kvetková, A., Horňák, T., Semerád, L., and Žáčková, D.

Abstract

Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021
Full Text
View/download PDF

3. Jaké dávky inhibitorů tyrozinkináz jsou v léčbě pacientů s chronickou myeloidní leukemií optimální?

Author

Žáčková, D., Čičátková, P., Kvetková, A., Horňák, T., Semerád, L., and Mayer, J.

Abstract

Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021

4. Překvapivý nález v kostní dřeni: co za ním je?

Author

Horňák, T., Holtánová, N., Křen, L., Skřičková, J., Hrazdirová, A., Mayer, J., and Žáčková, D.

Abstract

This case study describes the complex diagnostic and therapeutic process in an immunocompetent patient suffering from a disseminated nontuberculous mycobacteria infection caused by Mycobacterium avium complex. During the infection, the patient suffered from pancytopenia, liver damage and acute renal failure. Necrotizing granulomatosis was found in bone marrow and splenic tissue with no signs of infection macroscopically or using imaging methods. Diagnosis was eventually determined by microbial cultivation of splenic tissue. The patient was then prescribed targeted antituberculotic treatment, which led to clinical and laboratory improvement. [ABSTRACT FROM AUTHOR]

Published
2020

5. Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia.

Author

Mayer J, Čičátková P, Kováčová L, Jarošová M, Karas M, Jindra P, Klamová H, Poláková KM, Černá O, Cmunt E, Bělohlávková P, Žák P, Faber E, Papajík T, Stejskal L, Ježíšková I, Weinbergerová B, Jurček T, Horňák T, Žáčková D, Ransdorfová Š, Holzerová M, and Pavlík T

Abstract

The influence of t(v;22) sole, major route ACAs all (+8, n = 14; +Ph, n = 10; +19, n = 1), and -Y sole on progression-free survival. Survival curves are compared with those of patients with the standard t(9;22) translocation. Other ACAs or complex karyotypes did not influence survival., (© 2025 Wiley Periodicals LLC.)

Published
2025
Full Text
View/download PDF

6. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.

Author

Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, and Mayer J

Subjects
Humans, Tyrosine Kinase Inhibitors, Czech Republic, Chronic Disease, Protein Kinase Inhibitors therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myeloid
Published
2024
Full Text
View/download PDF

7. Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study.

Author

Horňák T, Semerád L, Žáčková D, Weinbergerová B, Šustková Z, Procházková J, Bělohlávková P, Stejskal L, Rohoň P, Faber E, Žák P, Mayer J, and Ráčil Z

Subjects
Heart Disease Risk Factors, Humans, Imatinib Mesylate adverse effects, Lipids, Prospective Studies, Protein Kinase Inhibitors, Pyrimidines, Risk Factors, Antineoplastic Agents, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results